| Popis: |
Jessica A Walsh,1 Heather Jones,2 Lotus Mallbris,2 Kristina Callis Duffin,3 Gerald G Krueger,3 Daniel O Clegg,1 Annette Szumski4 1Division of Rheumatology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; 2Inflammation and Immunology,Global Medical Affairs, Pfizer, Collegeville, PA, USA; 3Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA; 4Pfizer Business Unit (PBU) Syneos Health, Princeton, NJ, United States Background: The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments. Methods: The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland–Altman plots, and Kappa statistics. Results: Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87, and 0.90, respectively; all P |
